Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | EVP, CLO and Secretary | March 03, 2025 | March 05, 2025 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Senior VP & General Counsel | March 20, 2023 | March 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date March 03, 2025 · Filed March 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,002 |
Reported balance
After 2025-03-03 transaction · row 1
1 source rowRow 1 · 2025-03-03 · Grant · Acquired 757 · Balance 8,002 F1: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $243.53 · Expires 2035-03-03 | Direct | 1,529 |
Reported balance
After 2025-03-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-03 · Grant · Acquired 1,529 · Balance 1,529 F2: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
F2: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
Voyager Therapeutics, Inc.
Report date March 20, 2023 · Filed March 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,200 |
Reported balance
After 2023-03-20 transaction · row 1
1 source rowRow 1 · 2023-03-20 · Sale · Disposed 4,410 · Balance 102,200 F1: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the Reporting Person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2023. The Reporting Person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.94, inclusive. The Reporting Person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the Reporting Person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2023. The Reporting Person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.94, inclusive. The Reporting Person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foundation Medicine, Inc.
Report date July 31, 2018 · Filed August 02, 2018
Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-07-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-07-31 · Other · Disposed 76,494 · Balance 28,709 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Row 2 · 2018-07-31 · Other · Disposed 28,709 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.
F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.
F3: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2025 Filed Mar 5, 2025 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 1,529 | $0.00 Strike: $243.53 | $0.00 |
DisclosureSEC source: 0001735276-25-000035 · edgardoc.xml · derivative · entry 2 Hesslein Robert W. · CIK 0001585018 · EVP, CLO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,529 Underlying: Common Stock · 1,529 shares Expires 2035-03-03 F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 757 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000035 · edgardoc.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · EVP, CLO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,002 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 7,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000096 · edgardoc.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · EVP, CLO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,245 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:47 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 4,410 | $7.76 | $34,221.60 |
DisclosureSEC source: 0001104659-23-035638 · tm2310223-1_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,200 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the Reporting Person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2023. The Reporting Person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the Reporting Person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the Reporting Person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2023. The Reporting Person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.94, inclusive. The Reporting Person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 01:58 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 3,297 | $7.45 | $24,562.65 |
DisclosureSEC source: 0001104659-23-024424 · tm237526-5_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,610 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the Reporting Person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 16, 2023. The Reporting Person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the Reporting Person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the Reporting Person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 16, 2023. The Reporting Person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.34 to $7.58, inclusive. The Reporting Person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:52 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 2,868 | $7.67 | $21,997.56 |
DisclosureSEC source: 0001104659-23-022429 · tm236923-1_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,907 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2023. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2023. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.42 to $7.79, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:57 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 792 | $10.34 | $8,189.28 |
DisclosureSEC source: 0001104659-23-005053 · tm233882-3_4seq1.xml · nonDerivative · entry 2 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,775 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2023. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2023. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.19 to $10.75, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:57 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 1,396 | $9.57 | $13,359.72 |
DisclosureSEC source: 0001104659-23-005053 · tm233882-3_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,567 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2023. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2023. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.19 to $10.18, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 20:34 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 2,786 | $8.25 | $22,984.50 |
DisclosureSEC source: 0001104659-22-043244 · tm2212086-1_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,963 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.60, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:39 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 58 | $8.68 | $503.44 |
DisclosureSEC source: 0001104659-22-037153 · tm2210284-3_4seq1.xml · nonDerivative · entry 2 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,749 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.695, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:39 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 4,897 | $8.29 | $40,596.13 |
DisclosureSEC source: 0001104659-22-037153 · tm2210284-3_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,807 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.66 to $8.655, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:37 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 4,100 | $3.55 | $14,555.00 |
DisclosureSEC source: 0001104659-22-025672 · tm227228-2_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,704 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 16, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 16, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.49 to $3.67, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:42 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 3,252 | $3.36 | $10,926.72 |
DisclosureSEC source: 0001104659-22-023834 · tm226802-2_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,804 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.43, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 13, 2022 Filed Jan 19, 2022 01:06 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001104659-22-005022 · tm223208-1_4seq1.xml · derivative · entry 2 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2032-01-13 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 13, 2022. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| January 13, 2022 Filed Jan 19, 2022 01:06 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005022 · tm223208-1_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,056 F1 · shares: Consists of shares of common stock issuable under an aggregate of 20,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 13, 2022. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:44 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 3,292 | $4.95 | $16,295.40 |
DisclosureSEC source: 0001104659-21-047689 · tm2112333-1_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,056 F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 20:11 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-040307 · tm2110581-3_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,348 F1 · shares: Consists of shares of common stock issuable under an aggregate of 30,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, March 19, 2021. The RSU award vests over two years, with 1/2 of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and the remainder of the shares of common stock underlying the RSU award vesting on the two-year anniversary of such vesting commencement date, subject to the Reporting Person's continued service. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:57 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 68,000 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001104659-21-025273 · tm217191-2_4seq1.xml · derivative · entry 2 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2031-02-16 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 16, 2021. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:57 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-025273 · tm217191-2_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,348 F1 · shares: Consists of shares of common stock issuable under an aggregate of 34,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 16, 2021. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:08 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 3,186 | $7.55 | $24,054.30 |
DisclosureSEC source: 0001104659-21-023939 · tm216891-2_4seq1.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,348 F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:24 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 3,091 | $8.51 | $26,304.41 |
DisclosureSEC source: 0001104659-20-044247 · a4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,534 F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2020. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.10 to $8.52, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:20 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001104659-20-019455 · a4.xml · derivative · entry 2 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-02-10 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 10, 2020. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:20 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-019455 · a4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,625 F1 · shares: Consists of shares of common stock issuable under an aggregate of 27,500 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 10, 2020. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 01:28 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 168,750 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001104659-19-019772 · a4.xml · derivative · entry 2 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires 2029-04-01 F1 · shares: This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). F3 · derivative.exercise_date: The Vesting Commencement Date of the option is April 1, 2019. The option vests over four years, with 25% of the shares of Common Stock underlying the option vesting upon the one-year anniversary of the Vesting Commencement Date and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment by the Company and other terms and conditions set forth in the applicable option agreement. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 01:28 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-019772 · a4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 F1 · shares: This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). F2 · balance_after: Includes shares of common stock underlying one or more restricted stock unit ("RSU") awards. Each RSU represents the right to receive one share of common stock, par value $0.001 per share, of the Company (the "Common Stock") upon vesting, subject to the Reporting Person's continued employment by the Company and other terms and conditions set forth in the applicable RSU agreement. The RSU awards vest over three years, with 33.33% of the shares of Common Stock underlying the award vesting upon the one-year anniversary of the vesting commencement date (the "Vesting Commencement Date") of such award and the remainder vesting in equal annual installments thereafter. The Vesting Commencement Date of this RSU award is April 1, 2019. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:06 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | OtherCommon Stock | 28,709 | $137.00 | $3,933,133.00 |
DisclosureSEC source: 0001209191-18-044926 · doc4.xml · nonDerivative · entry 2 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3 · shares: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:06 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | OtherCommon Stock | 76,494 | $137.00 | $10,479,678.00 |
DisclosureSEC source: 0001209191-18-044926 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,709 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2 · shares: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:08 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 2,520 | $136.66 | $344,383.20 |
DisclosureSEC source: 0001209191-18-041550 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,203 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on July 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on (1) April 1, 2016 in Table I of the Form 4 filed on April 6, 2016, (2) May 1, 2017 in Table I of the Form 4 filed on May 3, 2017 and (3) April 1, 2018 in Table I of the Form 4 filed on April 3, 2018. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting events related to this securities sale. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 16:11 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionStock Option (right to buy) · Derivative | 2,344 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-18-022887 · doc4.xml · derivative · entry 4 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,344 shares Expires 2023-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on May 21, 2013 and vested in equal quarterly installments over a four-year period beginning on April 1, 2014 until fully vested on January 1, 2018. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 16:11 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 1,585 | $74.88 | $118,684.80 |
DisclosureSEC source: 0001209191-18-022887 · doc4.xml · nonDerivative · entry 3 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,723 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F3 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.60 to $75.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F4 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 16:11 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionCommon Stock | 2,344 | $7.12 | $16,689.28 |
DisclosureSEC source: 0001209191-18-022887 · doc4.xml · nonDerivative · entry 2 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 16:11 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | GrantCommon Stock | 8,621 | $78.75 | $678,903.75 |
DisclosureSEC source: 0001209191-18-022887 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,964 F1 · shares: Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in equal quarterly installments over a three-year period with the first installment vesting on July 1, 2018. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 18,021 | $64.30 | $1,158,750.30 |
DisclosureSEC source: 0001209191-18-004227 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,343 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.68 to $67.70, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 17:18 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 472 | $64.00 | $30,208.00 |
DisclosureSEC source: 0001209191-18-001127 · doc4.xml · nonDerivative · entry 2 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,364 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on January 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.73 to $64.12, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F4 · balance_after: The reporting person previously reported the restricted stock units granted to the reporting person on May 1, 2017 in Table I of the Form 4 filed on May 3, 2017. As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 17:18 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 1,392 | $64.00 | $89,088.00 |
DisclosureSEC source: 0001209191-18-001127 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,836 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on January 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.73 to $64.12, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 16:02 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 663 | $38.80 | $25,724.40 |
DisclosureSEC source: 0001209191-17-055736 · doc4.xml · nonDerivative · entry 2 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,228 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on October 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F4 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.50 to $38.80, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F5 · balance_after: The reporting person previously reported the restricted stock units granted to the reporting person on May 1, 2017 in Table I of the Form 4 filed on May 3, 2017. As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 16:02 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 1,502 | $38.80 | $58,277.60 |
DisclosureSEC source: 0001209191-17-055736 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,891 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on October 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.45 to $38.80, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| July 06, 2017 Filed Jul 7, 2017 16:02 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 452 | $38.84 | $17,555.68 |
DisclosureSEC source: 0001209191-17-044355 · doc4.xml · nonDerivative · entry 3 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,393 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on July 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $36.85 to $40.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F6 · balance_after: The reporting person previously reported the restricted stock units granted to the reporting person on May 1, 2017 in Table I of the Form 4 filed on May 3, 2017. As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| July 06, 2017 Filed Jul 7, 2017 16:02 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 1,246 | $38.84 | $48,394.64 |
DisclosureSEC source: 0001209191-17-044355 · doc4.xml · nonDerivative · entry 2 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,845 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on July 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $36.85 to $40.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F5 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| July 06, 2017 Filed Jul 7, 2017 16:02 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 3,372 | $38.84 | $130,968.48 |
DisclosureSEC source: 0001209191-17-044355 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,091 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on June 30, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $36.85 to $40.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on July 15, 2015 in Table I of the Form 4 filed on July 17, 2015. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:21 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionStock Option (right to buy) · Derivative | 2,344 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-17-039154 · doc4.xml · derivative · entry 4 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,344 Underlying: Common Stock · 2,344 shares Expires 2023-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on May 21, 2013 and vests in equal quarterly installments over a four-year period beginning on April 1, 2014. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:21 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionStock Option (right to buy) · Derivative | 4,689 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001209191-17-039154 · doc4.xml · derivative · entry 3 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,689 shares Expires 2023-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on March 7, 2013 and vests in equal quarterly installments over a four-year period beginning on June 7, 2013. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:21 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionCommon Stock | 2,344 | $7.12 | $16,689.28 |
DisclosureSEC source: 0001209191-17-039154 · doc4.xml · nonDerivative · entry 2 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:21 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionCommon Stock | 4,689 | $4.16 | $19,506.24 |
DisclosureSEC source: 0001209191-17-039154 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2017 Filed May 16, 2017 16:06 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 1,009 | $33.87 | $34,174.83 |
DisclosureSEC source: 0001209191-17-032611 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,430 Read SEC document |
| May 01, 2017 Filed May 3, 2017 16:01 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | GrantCommon Stock | 16,367 | $35.80 | $585,938.60 |
DisclosureSEC source: 0001209191-17-029596 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,439 F1 · shares: Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in equal quarterly installments over a three-year period with the first installment occurring on August 1, 2017. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:05 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 1,233 | $31.96 | $39,406.68 |
DisclosureSEC source: 0001209191-17-025573 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,072 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 16:02 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 6,231 | $31.67 | $197,335.77 |
DisclosureSEC source: 0001209191-17-021681 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,305 F1 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.53 to $31.95, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 16:07 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 1,426 | $18.49 | $26,366.74 |
DisclosureSEC source: 0001209191-17-001962 · doc4.xml · nonDerivative · entry 2 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,536 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on January 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F5 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:07 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 3,256 | $17.41 | $56,686.96 |
DisclosureSEC source: 0001209191-17-001962 · doc4.xml · nonDerivative · entry 1 Hesslein Robert W. · CIK 0001585018 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,962 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on December 30, 2016. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $17.41 to $17.56, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on July 15, 2015 in Table I of the Form 4 filed on July 17, 2015. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.